Projekt

Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5)

Laufend - Rekrutierung – beendet · 2015 bis 2099

Schittenhelm Marcus, Munz Jeannine, Quinter Janine